These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23649428)

  • 1. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response.
    Odenthal M; Bollschweiler E; Grimminger PP; Schröder W; Brabender J; Drebber U; Hölscher AH; Metzger R; Vallböhmer D
    Int J Cancer; 2013 Nov; 133(10):2454-63. PubMed ID: 23649428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.
    Odenthal M; Hee J; Gockel I; Sisic L; Schmitz J; Stoecklein NH; Driemel C; Möhlendick B; Schmidt T; Knoefel WT; Lang H; Büttner R; Ott K; Vallböhmer D
    Int J Cancer; 2015 Jul; 137(1):230-7. PubMed ID: 25429911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
    Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
    Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
    Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
    Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
    Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
    Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
    Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
    Langer R; Specht K; Becker K; Ewald P; Bekesch M; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Clin Cancer Res; 2005 Oct; 11(20):7462-9. PubMed ID: 16243820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.
    Slotta-Huspenina J; Drecoll E; Feith M; Habermehl D; Combs S; Weichert W; Bettstetter M; Becker K; Langer R
    J Transl Med; 2018 Apr; 16(1):109. PubMed ID: 29695253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
    Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy.
    Ko MA; Zehong G; Virtanen C; Guindi M; Waddell TK; Keshavjee S; Darling GE
    Ann Thorac Surg; 2012 Oct; 94(4):1094-102; discussion 1102-3. PubMed ID: 22939244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer.
    Ruol A; Portale G; Castoro C; Merigliano S; Cagol M; Cavallin F; Chiarion Sileni V; Corti L; Rampado S; Costantini M; Ancona E
    Ann Surg Oncol; 2007 Nov; 14(11):3243-50. PubMed ID: 17713823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
    Tanaka K; Miyata H; Yamasaki M; Sugimura K; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S607-15. PubMed ID: 23838916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
    Drebber U; Lay M; Wedemeyer I; Vallböhmer D; Bollschweiler E; Brabender J; Mönig SP; Hölscher AH; Dienes HP; Odenthal M
    Int J Oncol; 2011 Aug; 39(2):409-15. PubMed ID: 21567082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer.
    Nakamura T; Hayashi K; Ota M; Eguchi R; Ide H; Takasaki K; Mitsuhashi N
    Am J Surg; 2004 Sep; 188(3):261-6. PubMed ID: 15450831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
    Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
    Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.